SSMF

Keysight and Nokia Bell Labs Achieve Record Symbol Rate of 260 GBaud Transmission in Coherent Optical Communications

Retrieved on: 
Thursday, September 22, 2022

Leveraging high symbol rate systems increases the aggregate per-wavelength information rate to reduce the cost-per-bit in optical systems.

Key Points: 
  • Leveraging high symbol rate systems increases the aggregate per-wavelength information rate to reduce the cost-per-bit in optical systems.
  • This enables R&D of transmission systems operated with symbol rates up to 260 GBaud and achieving net bitrates greater than 2 Tbit/s in coherent optical communications.
  • Keysight is honored to work with Nokia Bell Labs on achieving 260 GBaud, said Dr. Joachim Peerlings, vice president of Network and Data Center Solutions at Keysight.
  • We achieved this outstanding record of maximum symbol rate of 260 GBaud by leveraging enabling technologies and the expertise of several partners, said Hak Mardoyan, Senior Research Scientist, Nokia Bell Labs.

Gonçalo Castelo-Branco receives the Hans Wigzell Research Foundation's science prize amounting to SEK 925,000

Retrieved on: 
Friday, September 16, 2022

STOCKHOLM, Sept. 16, 2022 /PRNewswire/ --The Hans Wigzell Research Foundation (Hans Wigzells Forskningsstiftelse) awards its annual scientific prize to Professor Gonalo Castelo-Branco at Karolinska Institutet (KI).

Key Points: 
  • STOCKHOLM, Sept. 16, 2022 /PRNewswire/ --The Hans Wigzell Research Foundation (Hans Wigzells Forskningsstiftelse) awards its annual scientific prize to Professor Gonalo Castelo-Branco at Karolinska Institutet (KI).
  • Professor Gonalo Castelo-Branco receives the prize of SEK 925,000 for his important research around oligodendrocytes a cell type which plays important roles in relation to how the human brain develops and functions.
  • In his research, Professor Castelo-Branco has shown how a cell's DNA can be controlled to develop into an oligodendrocyte.
  • His research has already helped build a better understanding of multiple sclerosis (MS) and can hopefully also lead to improved therapy against this difficult disease.